Key facts
- Agatha’s last known valuation is $22.6M (Nov 2021).
- It has raised $8.0M; the latest was PE Growth/Expansion in Apr 2025.
- Notable investors include Salesforce Ventures, Japan Finance Corporation, GMO Venture Partners, One Capital (Tokyo), ARCHIMED — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Agatha
- ·The full record, as it builds
Funding rounds
No funding rounds for Agatha are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Agatha
Developer of a document management platform intended to organize the healthcare and life sciences industry's workflow. The company's platform provides standard modules and cloud services for clinical research and clinical trials to medical institutions and pharmaceutical companies, enabling clients to optimize the quality in managing clinical documentation and processes.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2015
- Employees
- 58
- Website
- agathalife.com/
- Ownership
- Privately Held (backing)
Agatha doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Agatha shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Agatha in its N-PORT filings yet. We sweep new filings monthly.